TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement - Marketable Securities - Schedule of Marketable Securities (Details)

Fair Value Measurement - Marketable Securities - Schedule of Marketable Securities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Cost	$ 9,266,613
Accrued Income	18,472
Unrealized Gains
Unrealized Losses	(20,124)
Fair Value	9,264,961us-gaap_AvailableForSaleSecurities
Fair Value, Inputs, Level 2 [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	9,266,613
Accrued Income	18,472
Unrealized Gains
Unrealized Losses	(20,124)
Fair Value	9,264,961
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,795
Accrued Income
Unrealized Gains
Unrealized Losses
Fair Value	1,795
Fair Value, Inputs, Level 2 [Member] \| US Agency Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	297,699
Accrued Income	360
Unrealized Gains
Unrealized Losses	(141)
Fair Value	297,918
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	3,430,000
Accrued Income	10,653
Unrealized Gains
Unrealized Losses	(11,236)
Fair Value	3,429,417
Fair Value, Inputs, Level 2 [Member] \| Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,528,308
Accrued Income	5,037
Unrealized Gains
Unrealized Losses	(6,631)
Fair Value	1,526,714
Fair Value, Inputs, Level 2 [Member] \| Municipal Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	4,008,811
Accrued Income	2,422
Unrealized Gains
Unrealized Losses	(2,116)
Fair Value	$ 4,009,117